Skip to main content
. 2015 Sep 21;10(12):2687–2696. doi: 10.1021/acschembio.5b00655

Figure 3.

Figure 3

Development and characterization of additional DDR2 inhibitors. (A) Structures of DDR2 inhibitors 2, 3, 4, 5, and 6. (B) Enzymatic activities against DDR2 and SRC kinases and antiproliferative activity of DDR2 inhibitors against DDR2-mutated lung cancer cell lines.